Beijing: On July 25, China gave conditional approval to domestic firm Genuine Biotech’s Azvudine pill to treat certain adult patients with COVID-19, adding another oral treatment option against the coronavirus. The Azvudine tablet, which China approved in July last year to treat certain HIV-1 virus infections, has been given a conditional green light to treat adult patients with “normal type” COVID, the National Medical Products Administration said in a statement.
